Uniunea Europeană - letonă - EMA (European Medicines Agency)

ceva santé animale - tulatromicīns - antibakteriālie līdzekļi sistēmiskai lietošanai - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. slimības klātbūtne ganāmpulkā jānosaka pirms metapigaktiskas apstrādes. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. slimības klātbūtne ganāmpulkā jānosaka pirms metapigaktiskas apstrādes. the product should only be used if pigs are expected to develop the disease within 2–3 days. aitas: Ārstēšana agrīnā stadijā infekcijas pododermatitis (pamatnes puve), kas saistīts ar bīstamu dichelobacter nodosus nepieciešama sistēmiska ārstēšana.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - zāles obstruktīvu elpceļu slimību, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imūnsupresanti - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

vetoquinol - tulatromicīns - antibakteriālie līdzekļi sistēmiskai lietošanai - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. slimības klātbūtne ganāmpulkā jānosaka pirms metapigaktiskas apstrādes. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. slimības klātbūtne ganāmpulkā jānosaka pirms metapigaktiskas apstrādes. the product should only be used if pigs are expected to develop the disease within 2–3 days. aitas: Ārstēšana agrīnā stadijā infekcijas pododermatitis (pamatnes puve), kas saistīts ar bīstamu dichelobacter nodosus nepieciešama sistēmiska ārstēšana.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridīns - multiplā skleroze - other nervous system drugs - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Uniunea Europeană - letonă - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiski līdzekļi - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Uniunea Europeană - letonă - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - osteoporoze - kalcija homeostāze - qutavina is indicated in adults. osteoporozes ārstēšana sievietēm pēc menopauzes un vīriešiem ar paaugstinātu lūzuma risku. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. attieksmi pret osteoporozi saistīts ar ilgstošu sistēmisku glikokortikoīdu terapiju sievietēm, gan vīriešiem, paaugstināts lūzums.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

elanco gmbh - tulatromicīns - antibakteriālie līdzekļi sistēmiskai lietošanai - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. slimības klātbūtne ganāmpulkā jānosaka pirms metapigaktiskas apstrādes. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. slimības klātbūtne ganāmpulkā jānosaka pirms metapigaktiskas apstrādes. the product should only be used if pigs are expected to develop the disease within 2–3 days. aitas: Ārstēšana agrīnā stadijā infekcijas pododermatitis (pamatnes puve), kas saistīts ar bīstamu dichelobacter nodosus nepieciešama sistēmiska ārstēšana.